Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

ValiRx (VAL) Share Price

Price 0.525p on 27-03-2025 at 17:30:01
Change -0.05p -8.7%
Buy 0.55p
Sell 0.50p
Buy / Sell VAL Shares
Last Trade: Buy 186,915.00 at 0.535p
Day's Volume: 2,136,314
Last Close: 0.525p
Open: 0.575p
ISIN: GB00BLH13C52
Day's Range 0.525p - 0.575p
52wk Range: 0.525p - 4.35p
Market Capitalisation: £2m
VWAP: 0.526032p
Shares in Issue: 374m

ValiRx (VAL) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 186,915 0.535p Ordinary
16:26:52 - 27-Mar-25
Buy* 254 0.55p Ordinary
16:09:08 - 27-Mar-25
Buy* 50,000 0.535p Ordinary
16:08:59 - 27-Mar-25
Sell* 300,000 0.52p Ordinary
15:50:48 - 27-Mar-25
Buy* 250,000 0.54p Ordinary
15:45:43 - 27-Mar-25
Sell* 1,000,000 0.515p Ordinary
14:29:39 - 27-Mar-25
Sell* 221,652 0.53p Ordinary
14:18:28 - 27-Mar-25
Unknown* 100,000 0.575p Ordinary
09:08:43 - 27-Mar-25
Buy* 27,493 0.5785p Ordinary
08:51:27 - 27-Mar-25
Buy* 150,000 0.58p Ordinary
11:49:03 - 26-Mar-25
See more ValiRx trades

ValiRx (VAL) Share Price History

Time period:
to
Date Open High Low Close Volume
27th Mar 2025 (Thu) 0.575 0.575 0.525 0.525 2,136,314
26th Mar 2025 (Wed) 0.575 0.575 0.575 0.575 464,273
25th Mar 2025 (Tue) 0.575 0.575 0.575 0.575 1,190,908
24th Mar 2025 (Mon) 0.60 0.60 0.575 0.575 1,956,406
21st Mar 2025 (Fri) 0.60 0.60 0.60 0.60 764,784
20th Mar 2025 (Thu) 0.60 0.60 0.60 0.60 358,161
19th Mar 2025 (Wed) 0.60 0.60 0.60 0.60 438,093
18th Mar 2025 (Tue) 0.625 0.625 0.575 0.60 1,179,812
17th Mar 2025 (Mon) 0.625 0.625 0.625 0.625 266,714
14th Mar 2025 (Fri) 0.625 0.625 0.625 0.625 419,452
13th Mar 2025 (Thu) 0.625 0.625 0.60 0.625 23,042
12th Mar 2025 (Wed) 0.625 0.625 0.625 0.625 940,720
11th Mar 2025 (Tue) 0.625 0.625 0.625 0.625 1,459,000
10th Mar 2025 (Mon) 0.625 0.625 0.625 0.625 18,919
7th Mar 2025 (Fri) 0.625 0.625 0.625 0.625 4,088,645
6th Mar 2025 (Thu) 0.625 0.625 0.625 0.625 669,475
5th Mar 2025 (Wed) 0.625 0.625 0.625 0.625 504,869
4th Mar 2025 (Tue) 0.625 0.625 0.625 0.625 54,888
3rd Mar 2025 (Mon) 0.625 0.625 0.625 0.625 1,707,431
28th Feb 2025 (Fri) 0.625 0.625 0.625 0.625 762,998
See more ValiRx price history

ValiRx (VAL) Regulatory News

Date Source Headline
27th Mar 2025 7:00 am RNS Directorate Changes and new Advisory Board
21st Mar 2025 11:07 am RNS Director Disclosure Update
24th Feb 2025 7:00 am RNS Conclusion of Evaluation Project
3rd Feb 2025 7:00 am RNS Inaphaea Evaluation and Commercial Use Agreement
30th Jan 2025 7:00 am RNS Extension of Evaluation Agreement
29th Jan 2025 7:00 am RNS New Evaluation and Option Agreement
15th Jan 2025 12:47 pm RNS Holding(s) in Company
15th Jan 2025 11:29 am RNS Holding(s) in Company
14th Jan 2025 7:00 am RNS Holding(s) in Company
9th Jan 2025 11:37 am RNS Holding(s) in Company
See more ValiRx regulatory news

ValiRx (VAL) Share News

ValiRx shares fall as ends collaboration with Imperial College London

24th Feb 2025 16:20

(Alliance News) - ValiRx PLC on Monday said it has decided to return the Dual Kinase project to Imperial College London for further development, and will have no further financial commitment to the programme. Read More

AIM WINNERS & LOSERS: Strong 2024 for Quadrise and Rosebank

31st Dec 2024 10:58

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More

ValiRx extends TheoremRx exclusivity period to final May 31 deadline

31st Dec 2024 10:58

(Alliance News) - ValiRx PLC on Tuesday said it has extended the exclusivity period for a proposed sub-license agreement with TheoremRx Inc for its VAL201 therapeutic candidate, setting a final deadline of May 31. Read More

IN BRIEF: ValiRx extends Ambrose Healthcare exclusivity agreement

20th Nov 2024 18:09

ValiRx PLC - Essex, England-based life sciences company - Says subsidiary ValiSeek Ltd has granted a six-month extension to Ambrose Healthcare Ltd offered under the exclusive option agreement inked in December 2023 to execute an exclusive sub-license of ValiSeek's VAL401 asset. Ambrose Healthcare now has a further six-month period during which it can choose to exercise the option. VAL401 is in development for the treatment of pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Read More

ValiRX adds to streak of deals with cancer cell test materials win

19th Nov 2024 11:39

(Alliance News) - ValiRX PLC announced on Tuesday it will provide more cancer cell detection materials to UK biotech firm Amply Discovery Ltd. Read More

See more ValiRx news
FTSE 100 Latest
Value8,666.12
Change-23.47

Login to your account

Forgot Password?

Not Registered